Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

Gynecologic Oncology

Volumn 106, Issue 3, 2007, Pages 453-460

  Einstein, Mark H ^a,b,c   Kadish, Anna S ^a   Burk, Robert D ^a,b,c   Kim, Mimi Y ^a,b   Wadler, Scott ^d   Streicher, Howard ^e   Goldberg, Gary L ^a,b,c   Runowicz, Carolyn D ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Heat shock protein; HPV; HPV E7 protein; Immunotherapy

Indexed keywords

BCG VACCINE; HEAT SHOCK PROTEIN; SGN 00101; UNCLASSIFIED DRUG;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL; COLPOSCOPY; CROSS REACTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANK SUM TEST; REMISSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERRUCA VULGARIS;

ADULT; BACTERIAL PROTEINS; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHAPERONINS; COHORT STUDIES; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 34548128005     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.04.038     Document Type: Article

References (39)

1. IARC Handbooks of Cancer Prevention. Cervix Cancer Screening vol. 10 (2005), IARC Press, Lyon, France
2. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 1 (2003) 63-73
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 1 (1999) 12-19 [see comments]
4. Arends M.J., Buckley C.H., and Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J. Clin. Pathol. 51 2 (1998) 96-103
5. Schiffman M., and Kjaer S.K. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monographs 31 (2003) 14-19
6. Ferenczy A., and Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3 1 (2002) 11-16
7. Kadish A.S., Timmins P., Wang Y., Ho G.Y., Burk R.D., Ketz J., et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol., Biomarkers Prev. 11 5 (2002) 483-488
8. Einstein M.H., and Kadish A.S. Anogenital neoplasia in AIDS. Curr. Opin. Oncol. 16 5 (2004) 455-462
9. Kadish A.S., Ho G.Y., Burk R.D., Wang Y., Romney S.L., Ledwidge R., et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89 17 (1997) 1285-1293
10. Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Herrero R., Hutchinson M.L., et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J. Infect. Dis. 190 3 (2004) 458-467
11. McNeil C. Search for HPV treatment vaccine heats up, researchers optimistic. J. Natl. Cancer Inst. 98 14 (2006) 954-955 10.1093/jnci/djj314
12. Collins Y., Einstein M.H., Gostout B.S., Herzog T.J., Massad L.S., Rader J.S., et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol. Oncol. 102 3 (2006) 552-562
13. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 9509 (2006) 489-498
14. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev., Immunol. 4 1 (2004) 46-54
15. Galloway D.A. Papillomavirus vaccines in clinical trials. Lancet, Infect. Dis. 3 8 (2003) 469-475
16. Crum C.P., and Rivera M.N. Vaccines for cervical cancer. Cancer J. 9 5 (2003) 368-376
17. Kadish A.S., and Einstein M.H. Vaccine strategies for human papillomavirus-associated cancers. Curr. Opin. Oncol. 17 5 (2005) 456-461
18. Menoret A., Chandawarkar R.Y., and Srivastava P.K. Natural autoantibodies against heat-shock proteins hsp70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology 101 3 (2000) 364-370
19. Asea A., Kraeft S.K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6 4 (2000) 435-442
20. Wu W.Z., Liu K.D., Xie Q., and Wu H.S. The study on the expression of membrane HSP70 protein in H22 cell and its immunoprotective mechanism against carcinoma. J. Exp. Clin. Cancer Res. 18 4 (1999) 543-548
21. Derkay C.S., Smith R.J., McClay J., van Burik J.A., Wiatrak B.J., Arnold J., et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann. Otol. Rhinol. Laryngol. 114 9 (2005) 730-737
22. Goldstone S.E., Palefsky J.M., Winnett M.T., and Neefe J.R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45 4 (2002) 502-507
23. Palefsky J., Goldstone S., and Neefe J. HspE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long-term follow-up. International Human Papillomavirus Conference 2002, Paris, France (2002)
24. Burk R.D., Kadish A.S., Calderin S., and Romney S.L. Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. Am. J. Obstet. Gynecol. 154 5 (1986) 982-989
25. Abadi M.A., Ho G.Y., Burk R.D., Romney S.L., and Kadish A.S. Stringent criteria for histological diagnosis of koilocytosis fail to eliminate overdiagnosis of human papillomavirus infection and cervical intraepithelial neoplasia grade 1. Hum. Pathol. 29 1 (1998) 54-59
26. Brewer C.A., Wilczynski S.P., Kurosaki T., Daood R., and Berman M.L. Colposcopic regression patterns in high-grade cervical intraepithelial neoplasia. Obstet. Gynecol. 90 4 Pt 1 (1997) 617-621
27. Ferris D.G., and Litaker M. Interobserver agreement for colposcopy quality control using digitized colposcopic images during the ALTS trial. J. Low. Genit. Tract Dis. 9 1 (2005) 29-35
28. Trimble C.L., Piantadosi S., Gravitt P., Ronnett B., Pizer E., Elko A., et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin. Cancer Res. 11 13 (2005) 4717-4723
29. Keefe K.A., Schell M.J., Brewer C., McHale M., Brewster W., Chapman J.A., et al. A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol., Biomarkers Prev. 10 10 (2001) 1029-1035
30. Chu N.R., Wu H.B., Wu T.C., Boux L.J., Mizzen L.A., and Siegel M.I. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 5 5 (2000) 401-405
31. Kadish A.S., Burk R.D., Kress Y., Calderin S., and Romney S.L. Human papillomaviruses of different types in precancerous lesions of the uterine cervix: histologic, immunocytochemical and ultrastructural studies. Hum. Pathol. 17 (1986) 384-392
32. Ho G.Y., Palan P.R., Basu J., Romney S.L., Kadish A.S., Mikhail M., et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int. J. Cancer 78 5 (1998) 594-599
33. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003) 518-527
34. Hopman E.H., Kenemans P., and Helmerhorst T.J. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet. Gynecol. Surv. 53 2 (1998) 97-106
35. Choo Y.C., Chan O.L., Hsu C., and Ma H.K. Colposcopy in microinvasive carcinoma of the cervix-an enigma of diagnosis. Br. J. Obstet. Gynaecol. 91 11 (1984) 1156-1160
36. van Meir J.M., Wielenga G., and Drogendijk A. Colposcopic analysis of 20 patients with microinvasive carcinoma of the uterine cervix. Obstet. Gynecol. Surv. 34 11 (1979) 872-873
37. Gage J.C., Hanson V.W., Abbey K., Dippery S., Gardner S., Kubota J., et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet. Gynecol. 108 2 (2006) 264-272
38. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327 18 (1992) 1272-1278
39. Reich O., Lahousen M., Pickel H., Tamussino K., and Winter R. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet. Gynecol. 99 2 (2002) 193-196